Is Terns Pharmaceuticals, Inc. (TERN) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.0% / 30% | 7.7% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 0.0% / 33% | 7.7% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 0.4% / 33% | 98.4% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.0% / 33% | 7.7% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 0.4% / 33% | 98.4% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -29.1% | |
| Return on Assets (ROA) | -19.9% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$70M |
| Free Cash Flow | -$70M |
| Total Debt | $1M |
| Debt-to-Equity | 0.4 |
| Current Ratio | 19.5 |
| Total Assets | $364M |
Price & Trading
| Last Close | $53.17 |
| 50-Day MA | $41.27 |
| 200-Day MA | $21.69 |
| Avg Volume | 2.2M |
| Beta | -0.3 |
|
52-Week Range
$1.86
| |
About Terns Pharmaceuticals, Inc. (TERN)
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity, as well as TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Terns Pharmaceuticals, Inc. (TERN) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Terns Pharmaceuticals, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Terns Pharmaceuticals, Inc.'s debt ratio?
Terns Pharmaceuticals, Inc.'s debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.4%.
What are Terns Pharmaceuticals, Inc.'s key financial metrics?
Terns Pharmaceuticals, Inc. has a market capitalization of $6.0B. Return on equity stands at -29.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.